Submitted by Jeffrey Lake on Mon, 05/22/2017 - 2:08am In which country do you practice? * Please indicate your specialization * Hepatologist Gastroenterologist Infectious disease specialist Internal medicine specialist Primary care physician Other, please specify: Please indicate your specialization Other, please specify: What is your preferred method for online learning about recent advances in the management of hepatitis C virus (HCV) infection and/or HIV)? (more than one answer possible) * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries Other, please specify: What is your preferred method for online learning about recent advances in the management of hepatitis C virus (HCV) infection and/or HIV)? (more than one answer possible) Other, please specify: How aware are you of the current recommendations on who should be tested for HCV? * Very aware Aware Reasonably aware Not very aware Not aware How informed are you about the recently approved antiviral therapies for HCV (including the recently approved combination therapies) and those currently being investigated in clinical trials? * Very well informed Well informed Reasonably informed Poorly informed Not informed How aware are you of the different treatment options for the different HCV genotypes (including genotype 3)? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the optimal treatment options for patients with HCV with (compensated/decompensated) cirrhosis, and severe chronic kidney disease or end-stage renal disease? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How familiar are you with the optimal treatment options for patients with HCV who have failed prior therapy? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How familiar are you of the treatment options for HCV in children and adolescents? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How confident are you in treating patients with HCV with the new direct-acting antivirals? * Very confident Confident Reasonably confident Not very confident Not confident How confident are you in monitoring and managing adverse events of patients with HCV on treatment with new direct-acting antivirals? * Very confident Confident Reasonably confident Not very confident Not confident How familiar are you with the optimal treatment options for HIV/HCV co-infected patients? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How informed are you about the recently approved therapies for HIV and those currently being investigated in clinical trials? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with the mode of action of the newly emerging treatment options for HIV? * Very familiar, I have a complete understanding of the mode of action Familiar, I have a basic understanding of the mode of action I have heard of the mode of action, but cannot recall it Not familiar How informed are you about the different long term safety considerations for the available therapy options for HIV? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with the prevention and management of comorbidities in patients with HIV? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
